Inventor · disambiguated record
Ante Sven Lundberg
Also filed as: LUNDBERG ANTE · LUNDBERG ANTE S · LUNDBERG ANTE SVEN
17 granted patents·31 pending applications·23 citations·filing 2006–2025
89Inventor score
Files withCRISPR THERAPEUTICS AG30VERTEX PHARMA15CASEBIA THERAPEUTICS LTD LIABILITY PARTNERSHIP1VERTEX PHAMACEUTICALS INCORPORATED1WYETH CORP1
Top patents by PatentIndex Score
48 records- 0194US11559588B2Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disordersCRISPR THERAPEUTICS AG·Filed 2018·Granted Jan 24, 2023·12 cites·18 claims
- 0286US11459587B2Materials and methods for treatment of pain related disordersVERTEX PHARMA·Filed 2017·Granted Oct 4, 2022·3 cites·17 claims
- 0384US11866727B2Materials and methods for treatment of glycogen storage disease type 1ACRISPR THERAPEUTICS AG·Filed 2016·Granted Jan 9, 2024·4 cites·6 claims
- 0482US2025064980A1Materials and Methods for Treatment of Duchenne Muscular DystrophyVERTEX PHARMA·Filed 2024·Application pending·0 cites
- 0579US12442020B2Materials and methods for treatment of pain related disordersVERTEX PHARMA·Filed 2022·Granted Oct 14, 2025·0 cites·18 claims
- 0679US11427838B2Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disordersVERTEX PHARMA·Filed 2017·Granted Aug 30, 2022·1 cites·6 claims
- 0778US12053531B2Materials and methods for treatment of Duchenne Muscular DystrophyVERTEX PHARMA·Filed 2022·Granted Aug 6, 2024·0 cites·5 claims
- 0878US11369692B2Materials and methods for treatment of Duchenne Muscular DystrophyVERTEX PHARMA·Filed 2016·Granted Jun 28, 2022·1 cites·3 claims
- 0978US11083799B2Materials and methods for treatment of hereditary haemochromatosisCRISPR THERAPEUTICS AG·Filed 2017·Granted Aug 10, 2021·1 cites·16 claims
- 1078US2024226339A1Materials and Methods for Treatment of HemoglobinopathiesVERTEX PHARMA·Filed 2024·Application pending·0 cites
- 1176US11174469B2Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disordersCRISPR THERAPEUTICS AG·Filed 2017·Granted Nov 16, 2021·1 cites·11 claims
- 1275US2024318200A1Compositions and methods for gene editingCRISPR THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 1375US2024066150A1Materials and methods for treatment of pain related disordersVERTEX PHAMACEUTICALS INCORPORATED·Filed 2023·Application pending·0 cites
- 1473US12186406B2Materials and methods for treatment of hereditary haemochromatosisCRISPR THERAPEUTICS AG·Filed 2021·Granted Jan 7, 2025·0 cites·20 claims
- 1573US2024175014A1Materials and methods for treatment of alpha-1 antitrypsin deficiencyCRISPR THERAPEUTICS AG·Filed 2023·Application pending·0 cites
- 1672US2024229078A1Materials and methods for treatment of glycogen storage disease type 1aCRISPR THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 1772US2025242061A1Materials and Methods for Treatment of HemoglobinopathiesVERTEX PHARMA·Filed 2025·Application pending·0 cites
- 1872US2025041349A1CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses ThereofVERTEX PHARMA·Filed 2024·Application pending·0 cites
- 1971US2025171800A1Materials and Methods for Treatment of HemoglobinopathiesVERTEX PHARMA·Filed 2024·Application pending·0 cites
- 2070US2023227855A1Materials and Methods for Treatment of Myotonic Dystrophy Type 1 (DM) and Other Related DisordersVERTEX PHARMA·Filed 2022·Application pending·0 cites
- 2170US2023330270A1Materials and methods for treatment of friedreich ataxia and other related disordersCRISPR THERAPEUTICS AG·Filed 2023·Application pending·0 cites
- 2270US2022211874A1Materials and methods for treatment of hemoglobinopathiesVERTEX PHARMA·Filed 2022·Application pending·0 cites
- 2369US2022364082A1Compositions and methods for editing the angiopoietin-like 4 (angptl4) geneCRISPR THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 2467US2022340897A1Materials and methods for treatment of apolipoprotein c3 (apociii)-related disordersCRISPR THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 2566US2019201553A1Materials and methods for treatment of hemoglobinopathiesCRISPR THERAPEUTICS AG·Filed 2019·Application pending·0 cites
- 2666US2025235561A1Materials and methods for treatment of hereditary haemochromatosisCRISPR THERAPEUTICS AG·Filed 2025·Application pending·0 cites
- 2761US2020330609A1Materials and methods for treatment of hemoglobinopathiesCRISPR THERAPEUTICS AG·Filed 2017·Application pending·0 cites
- 2860US11920148B2Compositions and methods for gene editingCRISPR THERAPEUTICS AG·Filed 2018·Granted Mar 5, 2024·0 cites·18 claims
- 2959US11801313B2Materials and methods for treatment of pain related disordersVERTEX PHARMA·Filed 2017·Granted Oct 31, 2023·0 cites·10 claims
- 3059US11564997B2Materials and methods for treatment of friedreich ataxia and other related disordersCRISPR THERAPEUTICS AG·Filed 2017·Granted Jan 31, 2023·0 cites·14 claims
- 3158US12161674B2CRISPR-CAS9 modified CD34+ human hematopoietic stem and progenitor cells and uses thereofVERTEX PHARMA·Filed 2018·Granted Dec 10, 2024·0 cites·16 claims
- 3255US2019185849A1Compositions and methods for gene editingCRISPR THERAPEUTICS AG·Filed 2017·Application pending·0 cites
- 3352US11851653B2Materials and methods for treatment of alpha-1 antitrypsin deficiencyCRISPR THERAPEUTICS AG·Filed 2016·Granted Dec 26, 2023·0 cites·5 claims
- 3452US2020123570A1Materials and methods for treatment of apolipoprotein c3 (apociii)-related disordersCRISPR THERAPEUTICS AG·Filed 2017·Application pending·0 cites
- 3548US12043843B2Materials and methods for treatment of hemoglobinopathiesCRISPR THERAPEUTICS AG·Filed 2016·Granted Jul 23, 2024·0 cites·12 claims
- 3646US11407997B2Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disordersCRISPR THERAPEUTICS AG·Filed 2018·Granted Aug 9, 2022·0 cites·15 claims
- 3746US2021180091A1Materials and methods for treatment of hemoglobinopathiesVERTEX PHARMA·Filed 2018·Application pending·0 cites
- 3845US2018127786A1Compositions and methods for gene editingCASEBIA THERAPEUTICS LTD LIABILITY PARTNERSHIP·Filed 2017·Application pending·0 cites
- 3945US2020248168A1Compositions and methods for treatment of proprotein convertase subtilisin/kexin type 9 (pcsk9)-related disordersCRISPR THERAPEUTICS AG·Filed 2018·Application pending·0 cites
- 4044US2020216857A1Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disordersCRISPR THERAPEUTICS AG·Filed 2018·Application pending·0 cites
- 4144US2020095579A1Materials and methods for treatment of merosin-deficient cogenital muscular dystrophy (mdcmd) and other laminin, alpha 2 (lama2) gene related conditions or disordersCRISPR THERAPEUTICS AG·Filed 2018·Application pending·0 cites
- 4243US2020040061A1Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disordersCRISPR THERAPEUTICS AG·Filed 2018·Application pending·0 cites
- 4343US2021260219A1Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degenerationCRISPR THERAPEUTICS AG·Filed 2016·Application pending·0 cites
- 4441US2019365929A1Materials and methods for treatment of dystrophic epidermolysis bullosa (deb) and other collagen type vii alpha 1 chain (col7a1) gene related conditions or disordersCRISPR THERAPEUTICS AG·Filed 2018·Application pending·0 cites
- 4540US2019112353A1Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndromeCRISPR THERAPEUTICS AG·Filed 2017·Application pending·0 cites
- 4640US2006235046A1Use of an epidermal growth factor receptor kinase inhibitor (EGFR) in gefitinib resistant patientsWYETH CORP·Filed 2006·Application pending·0 cites
- 4738US2019038771A1Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndromeCRISPR THERAPEUTICS AG·Filed 2017·Application pending·0 cites
- 4835US2019048340A1Novel family of rna-programmable endonucleases and their uses in genome editing and other applicationsCRISPR THERAPEUTICS AG·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ante Sven Lundberg files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →